A new study from VTT Technical Research Centre of Finland has found that type 1 diabetes, or autoimmune diabetes, is preceded by diminished gut microbial diversity of the Clostridium leptum subgroup, elevated plasma leptin and enhanced glucose-stimulated insulin secretion. In the past, VTT researches have found that specific metabolic disturbances precede early beta cell autoimmunity markers in children who subsequently progress to type 1 diabetes. Questions remained, however, about the environmental causes and tissue-specific mechanisms leading to these disturbances.
In the new study the team, led by Matej Oresic, carried out a study using non-obese diabetic (NOD) mice that recapitulated the protocol used in the DIPP clinical study, followed up by independent studies in which NOD mice were studied in relation to the risk of diabetes progression. Researchers found that young female NOD mice that later progress to autoimmune diabetes exhibit the same metabolic pattern as prediabetic children. These metabolic changes are accompanied by enhanced glucose-stimulated insulin secretion, upregulation of insulinotropic amino acids in islets, elevated plasma leptin and adiponectin, and diminished gut microbial diversity of the Clostridium leptum subgroup.
The elucidation of early metabolic pathways associated with progression to type 1 diabetes points to novel avenues for early disease prevention. The ongoing efforts of VTT researchers are focused on the potential of specific bacteria from the C. leptum subgroup to help prevent type 1 diabetes.
This study was supported by the Finnish Funding Agency for Technology and Innovation Tekes, the Seventh Framework Program of the European Community, and Juvenile Diabetes Research Foundation.
The environmental factors and molecular mechanisms leading to type 1 diabetes are poorly understood and of great public health interest. The incidence of inflammatory and autoimmune diseases is rising faster than for any other major disease, and these diseases are affecting a wide spectrum of the population. The number of new cases of type 1 diabetes in European children less than 5 years of age is expected to double between 2005 and 2020.
